Market Insights Health Hospitals Inpatient Care

Treatment of Cardiovascular Diseases - Malaysia

Malaysia

In Malaysia, the Treatment of Cardiovascular Diseases market is expected to experience substantial growth in the coming years.
The revenue is projected to reach US$1.41bn by 2024.
Furthermore, it is anticipated that the market will continue to expand at an annual growth rate of 6.48% from 2024 to 2029, resulting in a market volume of US$1.93bn by the end of 2029.
When compared to other countries globally, in the United States is predicted to generate the highest revenue, with an estimated value of US$136.00bn in 2024.
Malaysia is experiencing a surge in the adoption of digital health technologies for the treatment of cardiovascular diseases.

Key regions: China, India, United States, France, Canada

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.